Eisai and Halozyme Sign Collaboration Agreement to Investigate Halaven® (Eribulin) and PEGPH20 in Metastatic Breast Cancer - Seite 2

"This is a very important collaboration in our continual drive to beat advanced breast cancer and further confirms the distinct mode of action of eribulin. We look forward to enrolling patients in the clinical trial and obtaining the results," comments Gary Hendler, President and CEO Eisai EMEA and President, Eisai Oncology Global Business Unit.

"This agreement marks the first clinical collaboration agreement for Halozyme and extends the study of PEGPH20 to a substantially wider population of patients with a partner that is a clear leader in the treatment of metastatic breast cancer," said Dr. Helen Torley, President and CEO, Halozyme Therapeutics.

Eribulin remains the only single agent chemotherapy to significantly improve overall survival in women with advanced breast cancer after anthracycline and taxane treatment. Advanced or metastatic breast cancer is a very difficult condition to treat and only 25.9% of women will survive beyond five years^[2].

Eribulin is indicated in the European Union for the treatment of women with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease^[3]. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments.

Eisai is dedicated to the discovery, development and production of innovative oncology therapies that can make a difference and impact the lives of patients and their families. This passion for people is part of Eisai's human health care (hhc) mission, which strives to better understand the needs of patients and their families to increase the benefits health care provides.

Notes to Editors  

PEGPH20 

PEGPH20 (PEGylated recombinant human hyaluronidase) is an investigational drug administered intravenously that targets the degradation of hyaluronan (HA), a major component of the extracellular matrix. By disrupting HA, PEGPH20 may inhibit tumour growth and promote the dispersion of chemotherapeutic agents.

PEGPH20 is currently under development in combination with chemotherapies for the treatment of metastatic pancreatic cancer and non-small cell lung cancer^[4],[5] with plans later for it to be studied in combination with an immunotherapy agent later this year.

Halaven^® (eribulin)  

Eribulin is indicated for the treatment of women with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments^[3].